Follow the latest news on ACR advocacy efforts through ACR@Work and through ACR breaking news and social media.
Carina Stanton is a freelance science journalist based in Denver.
Follow the latest news on ACR advocacy efforts through ACR@Work and through ACR breaking news and social media.
Carina Stanton is a freelance science journalist based in Denver.
Value-based care in rheumatology continues to evolve, and rheumatologists can stay active with advocacy efforts behind value-based care and other government relations initiatives.
The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.
As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…
After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…